Plus Therapeutics Inc (PSTV)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $26.64M
Last updated: Nov 13, 2026 at 4:00 PM ET
Plus Therapeutics Inc (PSTV) Stock Forecast
Analysts expect Plus Therapeutics (PSTV) to earn -$3.92 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.30M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 25.0% |
| Buy | 3 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 203.8%.
- Fiscal year ending Dec 31, 2026
- -$3.92
- EPS consensus, revenue $6.30M
- Fiscal year ending Dec 31, 2027
- -$2.40
- EPS consensus, revenue $19.14M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.92 | -$4.78 to -$3.39 | 4 | $6.30M | $4.00M to $10.53M | 4 |
| Dec 31, 2027 | -$2.40 | -$2.81 to -$1.98 | 4 | $19.14M | $10.00M to $28.00M | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 4 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 2 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.69.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.92 | -$3.92 | -$3.87 | N/A | -$3.69 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.40 | -$2.40 | -$2.37 | N/A | -$2.25 | N/A |
Frequently Asked Questions About PSTV
What is the PSTV stock forecast?
Consensus analyst estimates put Plus Therapeutics's EPS at -$3.92 for the fiscal year ending Dec 31, 2026, on revenue of $6.30M. The consensus rating from 4 analysts is Buy.
How do analysts rate PSTV stock?
Of 4 analysts covering Plus Therapeutics, 1 rates it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PSTV next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.92, with estimates from -$4.78 to -$3.39 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.40, with estimates from -$2.81 to -$1.98 from 4 analysts.
What revenue do analysts expect from Plus Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.30M, with estimates from $4.00M to $10.53M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $19.14M, with estimates from $10.00M to $28.00M.
How many analysts cover PSTV?
4 analysts rate Plus Therapeutics stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PSTV pages: Overview, Earnings, Forecast, Financials, Competitors